Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 2Other solid neoplasm 1

Conditions

Neoplasms 2Malignant Solid Tumors 1

Interventions

Cisplatin 3202Cyclophosphamide 3195Carboplatin 2977Radiotherapy 2790Paclitaxel 2718Gemcitabine 2572pembrolizumab 2385Bevacizumab 2209Docetaxel 2199Fluorouracil 1851Capecitabine 1833Oxaliplatin 1742Dexamethasone 1605Nivolumab 1581Doxorubicin 1501Rituximab 1488Magnetic Resonance Spectroscopy 1387Etoposide 1346Irinotecan 1248Leucovorin 1226Drug Therapy 1205Cytarabine 1130Pemetrexed 1076fludarabine 1063Specimen Handling 1017Vincristine 964Cetuximab 945Trastuzumab 945Prednisone 942Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
SAR125844 × Clear all
NCT01391533 2016-04-13

SARMET

Sanofi

Phase 1 Completed
72 enrolled
Other solid neoplasm

Malignant Solid Tumors

NCT02435121 2016-03-23

A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification

Sanofi

Phase 2 Completed
1 enrolled
Tumor-Agnostic

Neoplasms

NCT01657214 2016-02-17

SARMETA

Sanofi

Phase 1 Completed
70 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡